Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves’ Disease
The Journal of Clinical Endocrinology & Metabolism · 21.01.2026 · 111 (2) · e368-e374
DOI: 10.1210/clinem/dgaf433 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 01.08.2025. Verfasst von Keitaro Miyamura und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Excellence in Thyroid Care, Kuma Hospital, Kobe 650-0011, Japan. Hauptthemen laut MEDLINE: Graves Disease, Antithyroid Agents, Methimazole. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although antithyroid drugs (ATDs) are widely used as the first-line therapy for Graves’ disease, relapse after treatment discontinuation remains common. While a prolonged low-dose ATD therapy has been associated with improved remission rates, the impact of the minimal maintenance dose before discontinuation on relapse risk remains unclear.
Method
We conducted a retrospective cohort study using electronic medical records from a thyroid specialty hospital in Japan. Patients newly diagnosed with Graves’ disease between 2008 and 2024 who had discontinued methimazole (MMI) after receiving a minimal maintenance dose (≤2.5 mg/day) were included. Patients were categorized into 4 groups based on their final maintenance dose before discontinuation: 2.5 mg/day, >1.25 to ≤2.5 mg/day, 1.25 mg/day, and <1.25 mg/day. We evaluated the association between the minimal MMI dose before discontinuation and the 1-year risk of relapse using multivariable regression and propensity score–matched analyses.
Results
Among 4352 eligible patients, multivariable regression showed that, compared with the 2.5 mg/day group, the 1.25 mg/day group had a significantly lower risk of relapse within 1 year [risk ratio (RR) 0.46, 95% confidence interval (CI) 0.28-0.75], and the <1.25 mg/day group had the lowest risk (RR: 0.18, 95% CI: 0.05-0.73). The propensity score-matched analysis, consistent with the multivariable regression, showed that the 1.25 mg/day group had a lower risk of relapse compared with the 2.5 mg/day group (RR: 0.44, 95% CI: 0.23-0.85; 172 matched pairs).
Conclusion
Lower minimum maintenance doses of MMI before discontinuation, particularly doses <2.5 mg/day, may be associated with a reduced risk of relapse in patients with Graves’ disease. Clinicians should recognize the clinical relevance of the minimum maintenance dose in the treatment of Graves’ disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Excellence in Thyroid Care, Kuma Hospital, Kobe 650-0011, Japan.
ORCID-Profile: Eijun Nishihara, Akira Miyauchi, Takashi Akamizu
Zitieren
APA
Miyamura, K., Ito, M., Yamaoka, H., Hisakado, M., Nishihara, E., Fukata, S., Nishikawa, M., Miyauchi, A., & Akamizu, T. (2026). Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves’ Disease. The Journal of Clinical Endocrinology & Metabolism, 111(2), e368-e374. https://doi.org/10.1210/clinem/dgaf433
Vancouver
Miyamura K, Ito M, Yamaoka H, Hisakado M, Nishihara E, Fukata S, et al. Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves’ Disease. The Journal of Clinical Endocrinology & Metabolism. 2026;111(2):e368-e374. doi:10.1210/clinem/dgaf433
BibTeX
@article{Miyamura2026,
author = {Miyamura, Keitaro and Ito, Mitsuru and Yamaoka, Hiroyuki and Hisakado, Mako and Nishihara, Eijun and Fukata, Shuji and Nishikawa, Mitsushige and Miyauchi, Akira and Akamizu, Takashi},
title = {Impact of Minimal Dose Strategy Before Antithyroid Drug Discontinuation on Relapse Risk in Graves’ Disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {2},
pages = {e368--e374},
doi = {10.1210/clinem/dgaf433}
}
EUVIMED